4th Pediatric Infectious Diseases Conference
 
 
Home  Back   ISSN 0973 - 0958
 
User name :
Password :
FIND DIAGNOSIS
FIND DIAGNOSIS
Find Diagnosis
Pedi Poll
Today's Poll
Should teicoplannin, colistin be used in case of neonatal sepsis where culture does not reveal any organism_?
No, it should be used only after drug sensitivity report
Yes, under guidance of an infectious disease expert
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Lab Investigations and Pathophysiology
Lab Investigations and Pathophysiology
Dr Vishal Dublish, Dr Ira Shah

Continued...

Pathophysiology:

Pathology of ARDS: 3 distinct phases:

  • Exudative phase: Starts within few days after lung injury. It is characterized by:

    • Extensive epithelial cell injury especially to type I pneumocytes and basement membrane denudation.

    • Swelling of endothelial cells with widening of intercellular junctions.

    • Formation of hyaline membrane composed of fibrin and other matrix protein in alveolar ducts and airspaces.

    • Neutrophilic infiltration

    • Fibrin thrombi in alveolar capillaries and small pulmonary arteries.

  • Proliferative phase: This phase is most prominent in second or third week after onset of symptoms and is characterized by:

    • Resolution of neutrophilic infiltration

    • Cuboidal type II cells and squamous epithelium cover over denuded alveolar basement membrane

    • Migration of fibroblast and myofibroblasts through breaks in alveolar membrane

  • Fibrotic Phase: After few weeks. It is characterized by :

    • Architectural resolution of lung tissue

    • Type III elastic collagen is replaced by Type I rigid collagen causing stiff lung.

    • Interstitial fibrosis with or without cystic and honeycomb changes leading to chronic pulmonary dysfunction and/or death.

Statistical Facts of ARDS and sepsis:

  • Sepsis especially gram negative with shock is the most common and frequent risk factor.

  • Frequency of ARDS with sepsis is 18-38%.

  • 18-25% of patients with gram negative sepsis develop ARDS.

  • Bacteremia with sustained hypotension is the harbinger for development of ARDS.

  • 30% of patients with septic shock develop ARDS while only 14% of patients with sepsis without shock develop ARDS.

  • When DIC is present, 38% patients developed ARDS, while only 17% developed ARDS when DIC was not present.

Fig. 1: Pathophysiology of ARDS


SEPSIS
SEPSIS
Release of inflammatory mediators (lipopolysaccharide, Cytokines, TNF-a, IL-1ß, IL-8 etc.)
Release of inflammatory mediators (lipopolysaccharide, Cytokines, TNF-a, IL-1, IL-8 etc.)
Acute systemic inflammatory response
Acute systemic inflammatory response
Neutrophil sequestration
(More immature, less deformable and less motile)
Neutrophil sequestration
Increased adhesiveness of neutrophils to endothelium
Increased adhesiveness of neutrophils to endothelium
Initially loose adhesion (Rolling effect)
Later on firm adhesions
Initially loose adhesion (Rolling effect)
Neutrophil migration (chemotaxis) from vascular space into pulmonary interstitium or alveoli
Neutrophil migration (chemotaxis) from vascular space into pulmonary interstitium or alveoli
Neutrophil activation and release of oxidative metabolites and proteolytic enzymes
Neutrophil activation and release of oxidative metabolites and proteolytic enzymes
Epithelial and endothelial cell injury
Loss of barrier function
Increased capillary permeability
Impaired gas exchange

Epithelial and endothelial cell injury
Acute lung injury / ARDS






 
 
Educational Section
 
Disclaimer:
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
 
copyright ©2011 website design & development by Levioza
Follow Us
Follow us on :
Folllow Us